| Fiscal period | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|
| Period End Date | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 |
|---|
| Product sales, net | 28,610.00 | 26,934.00 | 26,982.00 | 27,008.00 | 24,355.00 | 22,119.00 | 21,677.00 | 25,662.00 | 29,953.00 | 32,151.00 |
| Contract sales | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Royalty revenues | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Royalty and contract revenue | 144.00 | 182.00 | 299.00 | 297.00 | 334.00 | 330.00 | 450.00 | 445.00 | 437.00 | 488.00 |
| Contract and other revenues | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Contract revenue - SAB 101 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Total Revenues | 28,754.00 | 27,116.00 | 27,281.00 | 27,305.00 | 24,689.00 | 22,449.00 | 22,127.00 | 26,107.00 | 30,390.00 | 32,639.00 |
| Cost of sales | 6,251.00 | 6,498.00 | 5,657.00 | 6,601.00 | 4,572.00 | 4,675.00 | 4,853.00 | 4,371.00 | 4,261.00 | 4,006.00 |
| Research and development | 5,907.00 | 5,718.00 | 4,977.00 | 5,363.00 | 5,039.00 | 9,106.00 | 5,018.00 | 3,734.00 | 5,098.00 | 3,014.00 |
| Purchased in-process research and development | -- | 50.00 | 2,700.00 | 177.00 | 5,856.00 | -- | -- | -- | -- | -- |
| Acquired in-process research and development expenses | 4,663.00 | 1,155.00 | 944.00 | -- | -- | -- | -- | -- | -- | -- |
| Selling, general and administrative | 6,091.00 | 6,090.00 | 5,673.00 | 5,246.00 | 5,151.00 | 4,381.00 | 4,056.00 | 3,878.00 | 3,398.00 | 3,426.00 |
| Asset impairment | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| In-process research and development impairment | (4,180.00) | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27,092.00 | 19,511.00 | 19,951.00 | 17,387.00 | 20,618.00 | 18,162.00 | 13,927.00 | 11,983.00 | 12,757.00 | 10,446.00 |
| Operating Income (loss) | 1,662.00 | 7,605.00 | 7,330.00 | 9,918.00 | 4,071.00 | 4,287.00 | 8,200.00 | 14,124.00 | 17,633.00 | 22,193.00 |
| Interest expense | 977.00 | 944.00 | 935.00 | 1,001.00 | 984.00 | 995.00 | 1,077.00 | 1,118.00 | 964.00 | 688.00 |
| Gain on sale of oncology assets | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Gain on sale of unconsolidated affiliate | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Loss on sale of marketable securities | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Minority interest in joint venture | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Interest and other income, net | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Make-whole payment on convertible debt redemption | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Other income (expense), net | 6.00 | 198.00 | (581.00) | (639.00) | (1,418.00) | 1,868.00 | 676.00 | 523.00 | 428.00 | 154.00 |
| Income (loss) before provision for income taxes an and equity in loss of unconso | 690.00 | 6,859.00 | 5,814.00 | 8,278.00 | 1,669.00 | 5,160.00 | 7,799.00 | 13,529.00 | 17,097.00 | 21,659.00 |
| Provision (benefit) for income taxes | 211.00 | 1,247.00 | 1,248.00 | 2,077.00 | 1,580.00 | (204.00) | 2,339.00 | 8,885.00 | 3,609.00 | 3,553.00 |
| State: Current | 39.00 | (80.00) | (32.00) | (228.00) | 198.00 | 135.00 | 162.00 | 97.00 | 131.00 | 158.00 |
| State: Deferred | (386.00) | (170.00) | 154.00 | (185.00) | (97.00) | (42.00) | (17.00) | (20.00) | 28.00 | (21.00) |
| Foreign: Current | 519.00 | (381.00) | (232.00) | (185.00) | 155.00 | 124.00 | 175.00 | 54.00 | 261.00 | 212.00 |
| Foreign: Deferred | 106.00 | 39.00 | (101.00) | 47.00 | 38.00 | (1,224.00) | (21.00) | 60.00 | (77.00) | (51.00) |
| Federal: Current | 1,495.00 | (1,781.00) | (2,539.00) | (1,776.00) | 1,450.00 | 1,646.00 | 1,716.00 | 8,817.00 | 3,351.00 | 3,568.00 |
| Federal: Deferred | (1,562.00) | 1,126.00 | 1,502.00 | 250.00 | (164.00) | (843.00) | 324.00 | (123.00) | (85.00) | (313.00) |
| Equity in loss of unconsolidated affiliate | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Loss before cumulative effect of change in accounting principle | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Cumulative effect of change in accounting principle | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Consolidated Net Income (Loss) | 480.00 | 5,613.00 | 4,566.00 | 6,201.00 | 89.00 | 5,364.00 | 5,460.00 | 4,644.00 | 13,488.00 | 18,106.00 |
| Net loss attributable to noncontrolling interest | 0.00 | (52.00) | (26.00) | (24.00) | (34.00) | (22.00) | 5.00 | 16.00 | (13.00) | (2.00) |
| Net income (loss) attributable to common stockholders | 480.00 | 5,665.00 | 4,592.00 | 6,225.00 | 123.00 | 5,386.00 | 5,455.00 | 4,628.00 | 13,501.00 | 18,108.00 |
| Loss before cumulative effect of change in accounting principle | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Cumulative effect of change in accounting principle- Basic | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Net income (loss) per share - Basic | 0.38 | 4.54 | 3.66 | 4.96 | 0.10 | 4.24 | 4.20 | 3.54 | 10.08 | 12.37 |
| Loss before cumulative effect of change in accounting principle | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Cumulative effect of change in accounting principle- Diluted | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Net income (loss) per share - Diluted | 0.38 | 4.50 | 3.64 | 4.93 | 0.10 | 4.22 | 4.17 | 3.51 | 9.94 | 11.91 |
| Shares used in per share calculation - basic | 1,247.00 | 1,248.00 | 1,255.00 | 1,256.00 | 1,257.00 | 1,270.00 | 1,298.00 | 1,307.00 | 1,339.00 | 1,464.00 |
| Shares used in per share calculation - diluted | 1,255.00 | 1,258.00 | 1,262.00 | 1,262.00 | 1,263.00 | 1,277.00 | 1,308.00 | 1,319.00 | 1,358.00 | 1,521.00 |